• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

    10/3/23 7:00:00 AM ET
    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGBA alert in real time by email

    MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 1

    October 4, 2023

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    AGBA Group Holding Limited (NASDAQ:AGBA)

    Mr. Wing-Fai Ng, Group President of AGBA Group

    9:40 - 10:10

    Loop Industries, Inc. (NASDAQ:LOOP)

    Kevin C. O'Dowd, VP Communications

    10:15 - 10:45

    CoTec Holdings Corp. (OTCQB:CTHCF) (TSXV:CTH)

    Julian Treger, President / CEO

    10:50 - 11:20

    ASP Isotopes, Inc. (NASDAQ:ASPI)

    Paul Elliot Mann, CEO

    11:25 - 11:55

    Akari Therapeutics, plc (NASDAQ:AKTX)

    Rachelle Jacques, CEO

    12:00 - 12:30

    FendX Technologies, Inc. (OTCQB:FDXTF) (CSE:FNDX)

    Carolyn Jane Myers, CEO

    1:10 - 1:40

    NeuroSense Therapeutics, Ltd. (NASDAQ:NRSN)

    Alon Ben-Noon, Co-Founder, CEO & Director

    Postponed to November 1, 2023

    Coeptis Therapeutics Holdings, Inc., (NASDAQ:COEP)

    David Mehalick, President / CEO

    2:55 - 3:05

    Rakovina Therapeutics Inc. (TSXV:RKV)

    Jeffrey Bacha, Executive Chairman & David Hyman, President

    3:10 - 3:20

    Alpha Tau Medical, Inc. (NASDAQ:DRTS)

    Raphi Levy, CFO

    3:25 - 3:35

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    David Dodd, Chairman, President / CEO

    3:40 - 3:50

    Renforth Resources, Inc. (OTCQB:RFHRF) (CSE:RFR)

    Nicole Brewster, President & CEO

    3:55 - 4:05

    NeuroMetrix, Inc. (NASDAQ:NURO)

    Dr. Shai Gozani, CEO & Thomas Higgins, CFO

    Day 2

    October 5, 2023

    9:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 - 10:10

    Theriva Biologics (NYSE:TOVX)

    Steven A. Shallcross, CEO / CFO

    10:15 - 10:45

    Bioxytran, Inc. (OTCQB:BIXT)

    Mike Sheikh, Executive Vice President Business Development

    10:50 - 11:20

    Inspire Veterinary Partners, Inc. (NASDAQ:IVP)

    Kimball Carr, Chairman, President & CEO

    12:00 - 12:30

    BioLargo, Inc. (OTCQB:BLGO)

    Dennis Calvert, President / CEO

    1:10 - 1:40

    Nextech3D.ai, formerly known as "Nextech AR Solutions Corp" (OTCQX:NEXCF) (CSE:NTAR) (FSE: EP2)

    Evan Gappelberg, CEO

    1:45 - 2:15

    Sokoman Minerals Corp., (OTCQB:SICNF) (TSXV:SIC)

    Timothy Froude P. Geo. CEO, Pres & Director

    2:20 - 2:50

    Knightscope, Inc. (NASDAQ:KSCP) 

    William Santana Li Chairman & CEO

    2:55 - 3:05

    Cyngn, Inc. (NASDAQ:CYN)

    Lior Tal, CEO & Director

    3:10 - 3:20

    Citizens, Inc. (NYSE:CIA)

    Gerald W. Shields, Vice Chairman / CEO, & Jeff Conklin, CFO

    3:25 - 3:35

    Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)

    Michael Martino, CEO & Director

    3:40 - 3:50

    Steppe Gold, Ltd. (OTCQX:STPGF) (TSX:STGO)

    Aneel Singh, Exec. VP & Director

    3:55 – 4:05

    Regen Biopharma, Inc. (OTC:RGBP)

    David Koos, President / CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AKTX
    $AMPE
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    Knightscope Inc.
    $KSCP
    1/30/2025$16.00Buy
    H.C. Wainwright
    GeoVax Labs Inc.
    $GOVX
    11/11/2024$15.00Buy
    Alliance Global Partners
    ASP Isotopes Inc.
    $ASPI
    10/4/2024$4.50Buy
    Canaccord Genuity
    More analyst ratings

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hart Spencer

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    1/6/26 6:14:44 PM ET
    $LOOP
    Major Chemicals
    Industrials

    SEC Form 4 filed by CEO and CFO Shallcross Steven A

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    1/6/26 4:55:21 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Monahan John J

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    1/6/26 4:54:19 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hart Spencer bought $66,070 worth of shares (50,000 units at $1.32), increasing direct ownership by 14% to 410,370 units (SEC Form 4)

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    11/12/25 4:33:21 PM ET
    $LOOP
    Major Chemicals
    Industrials

    CEO Gaslightwala Abizer bought $19,540 worth of American Depositary Shares representing Ordinary Shares (21,000 units at $0.93), increasing direct ownership by 8% to 298,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    8/29/25 4:55:12 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

    Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala. In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate update highlighting the Company's progress in 2025, key scientific and operational milestones achieved, and how these advances position Akari for a potential transition to a clinical-stage oncology company in 2026. Utilizing its innovativ

    1/9/26 9:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics to Present at the 2026 Biotech Showcase

    In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA. Presentation details are as follows: Date/Time: Tuesday, January 13, 2026 at 9:30 AM PSTL

    1/8/26 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

    Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translational neuroscience, further strengthening NeuroSense's scientific leadership as it advances

    1/8/26 8:45:00 AM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    SEC Filings

    View All

    Loop Industries Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Loop Industries, Inc. (0001504678) (Filer)

    1/8/26 4:31:15 PM ET
    $LOOP
    Major Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Cyngn Inc.

    SCHEDULE 13G/A - Cyngn Inc. (0001874097) (Subject)

    1/7/26 12:03:05 PM ET
    $CYN
    EDP Services
    Technology

    ASP Isotopes Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/7/26 9:28:37 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Cyngn Partners with Chandler Automation, Expands into Agriculture

    MOUNTAIN VIEW, Calif., Dec. 23, 2025 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced that Chandler Automation has joined its dealer network and will begin offering Cyngn's autonomous DriveMod Tugger to food processors and packers in the agriculture sector. Chandler Automation is a full-service partner in factory automation, specializing in optical sorting, inspection, robotic palletizing, and custom processing machinery. Known for delivering tailored, high-performance systems, Chandler empowers food processors to reduce labor costs, boost efficiency, and stay competitive wi

    12/23/25 7:00:00 AM ET
    $CYN
    EDP Services
    Technology

    Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

    Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) --  -Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company  -Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited (NASDAQ:SKBL), a Cayman Islands exempted company (the "Company"), today announced a number of strategic changes to the Company's leadership, strategy and corporate headquarters. Appointment of Paul Mann as Executive Chairman Effective January 1, 2026, Paul E. Mann will become Executive Chairman of the Company. Mr. Mann has a 25-year career as an investor and entrepreneur. He is currently the Founder and Executiv

    11/6/25 8:15:00 AM ET
    $ASPI
    $SKBL
    Major Chemicals
    Industrials
    Engineering & Construction
    Consumer Discretionary

    Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

    BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Sara Hurvitz. "The formation of our SAB marks an important step in advancing Akari's scientific and clinical strategy, and we are honored to welcome Dr. Sara Hurvitz as its inaugural member," commented Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "In addition to her wealth of knowledge around ADCs, Dr. Hurvitz brings exceptional clinical expertise in the management of can

    10/30/25 8:35:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Financials

    Live finance-specific insights

    View All

    Cyngn Reports Third Quarter 2025 Financial Results

    Recent Operating Highlights Deployed the DriveMod Tugger at G&J Pepsi, the Largest Independent Pepsi Bottler in the USAU.S. Continental "definitely recommends" the DriveMod Tugger.Secured funding that extends Cyngn's cash runway through 2027, reinforcing balance-sheet stability and capacity to scale operations.Appointed Natalie Russell as Chief Financial Officer to strengthen financial leadership and operational discipline.Expanded the sales organization to the largest in company history, reflecting a more mature commercial posture.Deployed the DriveMod Tugger at Coats, marking another live industrial implementation of Cyngn's autonomous vehicle technology.Secured Cyngn's 23rd U.S. patent, c

    11/18/25 5:41:00 PM ET
    $CYN
    EDP Services
    Technology

    ASP Isotopes to Provide Quarterly Business Update Call on November 21, 2025 at 8:30am EST

    WASHINGTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced it will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. (Eastern Time). Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Webcast Link https://events.q4inc.com/attendee/428149635 Participant Dial-In Details Date: November 21, 2025Time: 8:30 a.m. ESTDial in: USA / International Tol

    11/17/25 4:31:40 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care